6-Amino quinazolinedione sulfonamides as orally active competitive AMPA receptor antagonists.
Orain, D., Ofner, S., Koller, M., Carcache, D.A., Froestl, W., Allgeier, H., Rasetti, V., Nozulak, J., Mattes, H., Soldermann, N., Floersheim, P., Desrayaud, S., Kallen, J., Lingenhoehl, K., Urwyler, S.(2012) Bioorg Med Chem Lett 22: 996-999
- PubMed: 22197388 
- DOI: https://doi.org/10.1016/j.bmcl.2011.12.009
- Primary Citation of Related Structures:  
3UA8 - PubMed Abstract: 
A new set of quinazolinedione sulfonamide derivatives as competitive AMPA receptor antagonist with improved properties compared to 1 is disclosed. By modulating physico-chemical properties, compound 29 was identified with a low ED(50) of 5.5mg/kg in an animal model of anticonvulsant activity after oral dosage.
Organizational Affiliation: 
Novartis Institute for Biomedical Research, Global Discovery Chemistry, Basel CH-4002, Switzerland. david.orain@novartis.com